{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["18(3)"],"submitter":["Gambichler T"],"pubmed_abstract":["<h4>Background</h4>The COVID-19 pandemic disrupted access to routine dermatologic care and may have delayed melanoma diagnosis and management. Evidence on the post-pandemic period and on hospital-based referral cohorts remains limited. We assessed melanoma presentations before, during and after the pandemic in three skin cancer centers in North Rhine-Westphalia, Germany.<h4>Methods</h4>We conducted a multicenter retrospective cohort study of inpatients with cutaneous melanoma grouped into Phase 1 (February 2017-February 2020), Phase 2 (March 2020-March 2023), and Phase 3 (April 2023-May 2024). The primary endpoint was Breslow tumor thickness (TT) among invasive melanomas, analyzed using multivariable log-linear regression adjusted for center, age, sex, anatomic site, and histologic subtype"],"journal":["Cancers"],"pagination":["539"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12896566"],"repository":["biostudies-literature"],"pubmed_title":["Melanoma Presentations Before, During, and After the COVID-19 Pandemic: A Multicenter Cohort Study from North Rhine-Westphalia, Germany."],"pmcid":["PMC12896566"],"pubmed_authors":["Colo C","Abu Rached N","Boms S","Gambichler T","Weyer-Fahlbusch SS","Susok L"],"additional_accession":[]},"is_claimable":false,"name":"Melanoma Presentations Before, During, and After the COVID-19 Pandemic: A Multicenter Cohort Study from North Rhine-Westphalia, Germany.","description":"<h4>Background</h4>The COVID-19 pandemic disrupted access to routine dermatologic care and may have delayed melanoma diagnosis and management. Evidence on the post-pandemic period and on hospital-based referral cohorts remains limited. We assessed melanoma presentations before, during and after the pandemic in three skin cancer centers in North Rhine-Westphalia, Germany.<h4>Methods</h4>We conducted a multicenter retrospective cohort study of inpatients with cutaneous melanoma grouped into Phase 1 (February 2017-February 2020), Phase 2 (March 2020-March 2023), and Phase 3 (April 2023-May 2024). The primary endpoint was Breslow tumor thickness (TT) among invasive melanomas, analyzed using multivariable log-linear regression adjusted for center, age, sex, anatomic site, and histologic subtype","dates":{"release":"2026-01-01T00:00:00Z","publication":"2026 Feb","modification":"2026-07-08T03:13:54.314Z","creation":"2026-07-08T03:08:33.972Z"},"accession":"S-EPMC12896566","cross_references":{"pubmed":["41682009"],"doi":["10.3390/cancers18030539"]}}